CYCLACEL PHARMA (NASDAQ:CYCC)
0.80
0.01 (1.23%)
| CYCLACEL PHARMA (NASDAQ:CYCC) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $0.81 | 52 Week High | $1.66 | ||
| Open | $0.81 | 52 Week Low | $0.23 | ||
| Day High | $0.81 | P/E | N/A | ||
| Day Low | $0.79 | EPS | $-1.11 | ||
| Volume | 67,457 | ||||
| More CYCC Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| CYCCP | 7 | MWA | 5 |
| CNY | 4 | DRR | 4 |
| INR | 4 | MS | 4 |
| URR | 4 | JNP | 3 |
| CNW | 2 | ALGN | 1 |
| ADM | 1 | CFX | 1 |
Entities who have mentioned CYCC
- Merriman Curhan Ford | View Related Stories »
- Morgan Stanley | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Stock Buyback | View Related Stories »
- Lazard | View Related Stories »
- UBS | View Related Stories »
- Factory Orders | View Related Stories »
- Trading Radar | View Related Stories »
- Dividend | View Related Stories »
- Collins Stewart | View Related Stories »
- Piper Jaffray | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- Deutsche Bank | View Related Stories »
- JMP Securities | View Related Stories »
- Barclays | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Robert W Baird | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
View All ReportsStreetInsider.com Reports on CYCC
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- Cyclacel Pharmaceuticals (CYCC) Receives Non-Compliance Notification From NASDAQ
- Cyclacel Pharmaceuticals (CYCC) Moves Up On Merriman Curhan's New "Buy" Rating, Aggressive Price Target
- Merriman Curhan Ford Initiates Coverage on Cyclacel Pharmaceuticals (CYCC) with a Buy
- Morning Movers 7/24: CIT, ACPW, ALGN, CYTR, SPWRA Higher; RIGL, RVBD, NTCT, SIMG, DECK Lower
View All Press ReleasesCompany Press Releases on CYCC
- NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
- Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting
- Cyclacel Pharmaceuticals Announces Third Quarter 2009 Financial Results
- Cyclacel Pharmaceuticals Receives Deficiency Notice From Nasdaq Global Select Market
- Cyclacel Pharmaceuticals Reports Survival Data From Phase 2 Sapacitabine Study in Elderly Patients With Acute Myeloid Leukemia
StreetInsider Reports on CYCC by Category
View All BlogsBlogs on CYCC
- Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships
- Cyclacel Pharmaceuticals CEO Speaks About His Company
- Cancer Stocks: Lagging Again
View All FilingsSEC Filings on CYCC
- Form 4 Cyclacel Pharmaceuticals For: Nov 06 Filed by: MORGAN STANLEY
- Form 4 Cyclacel Pharmaceuticals For: Nov 05 Filed by: MORGAN STANLEY
- Form 4 Cyclacel Pharmaceuticals For: Nov 02 Filed by: MORGAN STANLEY
- Form 8-K Cyclacel Pharmaceuticals For: Nov 03
- Form 8-K Cyclacel Pharmaceuticals For: Oct 27
Comments on recent CYCC articles
Comments on CYCC
No comments are currently available.
on Nov 13, 2009
at 03:55 PM ANDREW OLIVER SATCHELL EXCELLENT
Article: Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
on Feb 20, 2008
at 03:42 PM INSM A $3.00 dollar stock trading below a $1.00.
Article: Analyst Call of the Year: Collins Stewart on Encysive (ENCY)